Comparative in vitro activity of antifungal drugs against pathogens causing opportunistic mycoses in patients with tuberculosis, identified using the MIC Test Strip and Sensititre test systems
https://doi.org/10.54921/2413-0346-2025-13-4-34-39
Abstract
The activity of 10 antifungal drugs (fluconazole, itraconazole, voriconazole, posaconazole, ketoconazole; anidulafungin, caspofungin, micafungin; amphotericin B; flucytosine) was tested against 33 species of yeast and mycelial fungi (genus Acremonium, Alternaria, Aspergillus, Candida, Cryptococcus, Fusarium, Geotrichum, Paecilomyces, Penicillium, Rhizopus, Rhodotorula, Trichoderma, Trichosporon) using the MIC Test Strip (gradient diffusion method) and Sensititre (microdilution method) test systems. A comparative study of two commercial standardized test systems for determining fungal susceptibility to antifungal drugs demonstrated a high level of agreement between the results (identical and highly similar MIC values for the antifungals totaled approximately 86%). The 10 drugs tested differed significantly in their spectrum of activity against pathogens causing candidiasis, cryptococcosis, rare yeast mycoses, aspergillosis, mucormycosis, hyalohyphomycosis, and phaeohyphomycosis. A group of drugs with a broad spectrum of activity (itraconazole, voriconazole, posaconazole, ketoconazole, amphotericin B) and a group of drugs active against individual groups of fungi (fluconazole, anidulafungin, caspofungin, micafungin, flucytosine) were identified.
About the Authors
A. B. Kulko
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow City Department of Health
Russian Federation
Russian Federation
Moscow
S. G. Safonova
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow City Department of Health
Russian Federation
Russian Federation
Moscow
References
1. Гаврилов П.В., Шульгина М.В. Бронхолегочные микозы. Иллюстрированный обзор // Мед. альянс. – 2023. – Т.11. – № 2. – С. 40-49.
2. Диагностика и лечение микозов / Под ред. Д.Р. Хоспентала, М. Дж. Риналди; пер. с англ. под ред. Ю.В. Сергеева. – М.: ГЭОТАР-Медиа, 2013. – 448 с.
3. Кулько А.Б. Атлас условно-патогенных грибов рода Aspergillus – возбудителей бронхолегочных инфекций. – М.: Изд-во Типография «Новости», 2012. – 160 с.
4. Кулько А.Б. Бронхолегочные микозы у больных туберкулезом: состав и свойства возбудителей, лабораторная диагностика: Автореф. дис. … д-ра биол. наук. – М., 2020. – 49 с.
5. Кулько А.Б. Группы возбудителей оппортунистических пневмомикозов у больных туберкулезом: протокол лабораторного исследования, активность лекарственных препаратов // Туберкулез и социально значимые заболевания. – 2021. – Т. 9 – № 2 (34). – С. 32-37.
6. Лабораторная диагностика легочных микозов во фтизиатрической клинике / Метод. рекомендации № 24; сост.: Кулько А.Б., Сафонова С.Г., Иванушкина Т.Н., Ермачкова Е.В. – М., 2019. – 28 с.
7. Саттон Д., Фотергилл А., Ринальди М. Определитель патогенных и условно патогенных грибов / Пер. с англ. К.Л. Тарасова Ю.Н. Ковалева под ред. И.Р. Дорожковой – М.: Мир, 2001. – 468 с.
8. Сергеев А.Ю., Сергеев Ю.В. Грибковые инфекции. Руководство для врачей. – М.: Изд-во Бином, 2008. – 480 с.
9. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts / 3rd informational supplement. CLSI document M27-S3. – Wayne, PA, 2008.
10. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts /4th informational supplement. CLSI document M27-S4. - Wayne, PA, 2010. – 29 p.
11. Delma F.Z., Al-Hatmi A.M.S., Buil J.B. et al. Comparison of MIC test strip and Sensititre YeastOne with the CLSI and EUCAST broth microdilution reference methods for in vitro antifungal susceptibility testing of Cryptococcus neoformans // Antimicrob. Agents Chemother. – 2020. – Vol. 64. – P. e02261-19.
12. Denning D.W., Pleuvry A., Cole D.C. Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis // Bul. World Health Organ. – 2011. – Vol. 1, № 89 (12). – P. 864-872.
13. Hermida-Alava K., Pola S., García-Effrón G., Cuestas M.L. Comparison of MIC Test Strip and reference broth microdilution method for amphotericin B and azoles susceptibility testing on wild-type and non-wild-type Aspergillus species // Med. Mycol. – 2025. – Vol. 63. - № 2. – P. myaf006.
14. Hoog de G.S., Guarro J., Gene J., Figueras M.J. Atlas of clinical fungi. Electronic Version 3.1 – CBS: Reus, 2011. – URL: http://www.clinicalfungi.org/
15. Hosseini M., Shakerimoghaddam A., Ghazalibina M., Khaledi A. Aspergillus coinfection among patients with pulmonary tuberculosis in Asia and Africa countries. A systematic review and meta-analysis of cross-sectional studies // Microb. Pathog. – 2020. – Vol. 141. – Article 104018.
16. Liofilchem. https://www.liofilchem.com/images/brochure/mic_test_strip_patent/MTS24.pdf
17. Liofilchem. https://www.liofilchem.com/images/brochure/mic_test_strip_patent/MTS06.pdf
18. Liofilchem. https://www.liofilchem.net/pdf/mic/reading-guide.pdf
19. Peña D.E.R., Innocentini L.M.A.R., Saraiva M.C.P. et al. Oral candidiasis prevalence in human immunodeficiency virus-1 and pulmonary tuberculosis coinfection: A systematic review and meta-analysis // Microb. Pathog. – 2021. – Vol. 150. – Article 104720.
20. Pfaller M.A., Diekema D.J. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012 // J. Clin. Microbiol. – 2012. – Vol. 50. - № 9. – P. 2846-2856.
21. Siopi M., Leventaki S., Pachoulis I. et al. Evaluation of the MIC test strips for antifungal susceptibility testing of Candidozyma auris (Candida auris) using a representative international collection of isolates // J. Clin. Microbiol. – 2025. – Vol. 63. -№ 8. – P. e0039925.
22. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs for antifungal agents, version 12.0, 2025.
23. The European Committee on Antimicrobial Susceptibility Testing. Overview of antifungal ECOFFs and clinical breakpoints for yeasts, moulds and dermatophytes using the EUCAST E.Def 7.4, E.Def 9.4 and E.Def 11.0 procedures. Version 6.0, 2025.
24. Vena A., Muñoz P., Guinea J. et al. Fluconazole resistance is not a predictor of poor outcome in patients with cryptococcosis // Mycoses. – 2019. – Vol. 62. – № 5. – P. 441-449.
Review
For citations:
Kulko A.B., Safonova S.G. Comparative in vitro activity of antifungal drugs against pathogens causing opportunistic mycoses in patients with tuberculosis, identified using the MIC Test Strip and Sensititre test systems. Tuberculosis and socially significant diseases. 2025;13(4):34-39. (In Russ.) https://doi.org/10.54921/2413-0346-2025-13-4-34-39
Views:
55
JATS XML
Email this article 